AnaptysBio/$ANAB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AnaptysBio
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- Ticker
- $ANAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 104
- Headquarters
- San Diego, United States
- Website
- www.anaptysbio.com
AnaptysBio Metrics
BasicAdvanced
$1.5B
6.97
$7.00
0.41
-
Price and volume
Market cap
$1.5B
Beta
0.41
52-week high
$73.30
52-week low
$32.90
Average daily volume
451K
Financial strength
Current ratio
5.613
Quick ratio
5.538
Long term debt to equity
25.265
Total debt to equity
25.469
Interest coverage (TTM)
0.80%
Profitability
EBITDA (TTM)
65.714
Gross margin (TTM)
105.03%
Net profit margin (TTM)
246.96%
Operating margin (TTM)
61.93%
Effective tax rate (TTM)
3,562.75%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Valuation
Price to earnings (TTM)
6.968
Price to revenue (TTM)
13.322
Price to book
136.97
Price to tangible book (TTM)
136.97
Price to free cash flow (TTM)
-13.445
Free cash flow yield (TTM)
-7.44%
Free cash flow per share (TTM)
-3.627
Growth
What the Analysts think about AnaptysBio
Analyst ratings (Buy, Hold, Sell) for AnaptysBio stock.
Analyst projections of the future price of AnaptysBio stock.
Bulls say / Bears say
Jemperli’s commercial momentum is strengthening: global sales reached $644 million in the first half of 2026, up 34% year on year. That supports a growing royalty base for AnaptysBio. (Nasdaq)
The court dismissed Tesaro’s anticipatory-breach claim and rejected its request to cut royalty rates, protecting AnaptysBio’s contracted Jemperli economics while the main case proceeds. (GlobeNewswire)
Quimilza has a US FDA action date of 12 December 2026 for generalised pustular psoriasis, and Vanda’s licence gives AnaptysBio a 10% royalty on net sales. Approval would add a second commercial royalty stream. (SEC)
The main GSK and Tesaro contract case remains unresolved, with AnaptysBio seeking reversion of Jemperli rights; a negative judgment could materially harm its rights and financial position. (SEC)
AnaptysBio has sold future Jemperli royalties to Sagard, which has a contractual target of $600 million by March 2031 or $675 million later before AnaptysBio regains subsequent royalties. That limits the near-term cash benefit from Jemperli’s growth. (SEC)
After the spin-off, AnaptysBio says it does not expect to do further research and development and will mainly collect payments from licensees, leaving its fortunes concentrated in external products and counterparties. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
AnaptysBio Financial Performance
Revenues and expenses
AnaptysBio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AnaptysBio
Fund name | Fund size | $ANAB weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.10% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.10% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.09% |
iShares Ageing Population€AGED | $887M | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.